1 research outputs found
Seroprevalence of Human Parvovirus B19 among Voluntary Blood Donors in Chennai: A Cross Sectional study
BACKGROUND :
The transfusion transmitted emerging infectious agents has become a
real threat to the transfusion safety. Human parvovirus B19 is one of the
common viral infection worldwide with a potential threat of transfusion
transmission through blood and its products particularly affecting the high risk
groups. Introduction of screening test for detecting Human parvovirus B19
antibodies for blood donors needs further evaluation for its potential risk and
cost effectiveness.
AIM :
To find out the seroprevalence of Human parvovirus B19 among voluntary blood donors in Chennai.
MATERIALS AND METHODS :
106 blood samples from voluntary blood donors were collected in one
year period from July 2015 to June 2016 and were subjected to IgM and IgG
serological tests using NovaLisa Human parvovirus B19 ELISA kits. Data
analysis was done using SPSS software and Chi-square test was used to find
statistical significance.
RESULTS :
Among 106 voluntary blood donors, 44.3% of the donors were positive
for anti-B19V IgG and none were positive for anti-B19V IgM. There was a
statistically significant difference (p=0.018) in IgG positivity among different
age group. Percentage of IgG B19V seropositivity gradually increases along
with increase in age of the donors. Statistically significant difference (p=0.001)
in IgG positivity in different socioeconomic groups affecting lower
socioeconomic group more than the middle and higher groups. There was a
statistically significant difference (p=0.019) in IgG positivity during different
months in a year. Among 47 donors positive for IgG B19V, one was positive
for HBsAg and two were positive for anti-HCV.
CONCLUSION :
The seroprevalence of anti-B19V IgG in blood donors is 44.3%. All
donor samples in this study were seronegative for IgM. Further larger studies
are needed to confirm the possibility of transfusion transmission of Human
parvovirus B19, to estimate clinical impacts on recipients and to justify the
introduction of donor screening for Human parvovirus B19. Till then it is
imperative to screen blood components at least for high risk recipients